For decades, glioblastoma has defied medicine's best efforts, leaving most patients with little more than a year to live. Researchers at UCLA have now identified a protein called endocan — produced by the tumor's own blood vessels — as a hidden architect of that resistance, one that quietly signals cancer cells to withstand radiation and spread deeper into the brain. By interrupting this molecular conversation with an existing drug, scientists extended survival in preclinical models, offering not a cure, but something medicine has long needed: a clearer picture of how these tumors protect them
News-Medical.net
· Jan 08, 2025
· health
· 3 min de lectura
High
Verificación: Verificado
UCLA Scientists Identify Endocan as New Target for Glioblastoma Treatment
Glioblastoma patients face dire prognosis with average 12-15 month survival and only 5% five-year survival rate, making new treatment approaches critical.
◉
Health & Medicine
6220 artículos relacionados
Mix-and-match COVID boosters offer immune system flexibility, expert e…
The Conversation · 100% coincidencia
FDA poised to approve scaled COVID vaccine for children ages 5-11
Futurity: Research News · 99% coincidencia
Context matters: Why vaccinated people dominate COVID hospital numbers
The Canberra Times · 99% coincidencia
Pharma M&A Surge Amid Drug Price Scrutiny, Bird Flu Vaccination Push
Devdiscourse · 99% coincidencia
Global health agencies mobilize against mpox, COVID variants amid bird…
Devdiscourse · 99% coincidencia
Cobertura Relacionada
The New York Times · Jul 21
Why Epidemics Trigger Rage Against Health Care Workers
The New York Times examines why societies repeatedly direct hostility toward healthcare workers during epidemic outbreak…
News-Medical · Jul 21 Study finds no link between sleep chronotype and liver disease markersItalian researchers found no significant association between chronotype and liver fat or fibrosis in 119 adults with obe…
DD India · Jul 21 India Approves First Dengue Vaccine Qdenga for Ages 4-60India's drug regulator CDSCO has approved Qdenga, the country's first dengue vaccine, for ages 4-60. The Takeda-develope…
insightnews.com.au · Jul 21 Optical Dispenser's 28-Year Journey: Why Being Yourself Is Your SuperpowerSonya Broadhead, a 28-year optical industry veteran and co-owner of See Side Optical, reflects on her career evolution f…
Sesgo y Encuadre
⚖
Science journalism article presenting UCLA research on glioblastoma treatment with straightforward reporting and minimal detectable bias.
Bias Direction
center
Confidence
HIGH
Standard medical research reporting using expert authority and clinical significance framing. Presents findings as promising advancement without overstating claims or inserting editorial perspective.
aggressive and lethal
imperative
lethal type of brain cancer
Patient or survivor perspectives on glioblastoma treatment
Potential limitations or skeptical expert commentary on the research
Timeline for clinical trials or practical application
Cost or accessibility considerations for future treatments
Competing research approaches from other institutions
Impacto Geopolítico
🌎
UCLA scientists' discovery of endocan as a glioblastoma treatment target has no direct geopolitical implications; it is a medical research advancement with potential healthcare benefits.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
UCLA discovery of endocan as glioblastoma treatment target could create new biotech opportunities and expand oncology drug development market, with potential for combination therapies.
Market Signal
bullish
Confidence
MED
Biotechnology/Pharmaceutical
Medical Devices
Healthcare Services
Cancer Research
Hospital/Clinical Services
Patients with glioblastoma may gain access to more effective treatment options that improve survival rates and quality of life; however, new therapies typically carry high costs that could increase healthcare expenses for patients and insurers.
FDA may expedite review pathways for endocan-targeting therapies given high unmet medical need; healthcare systems may need to allocate resources for clinical trials; insurance coverage policies may evolve to include combination radiation-immunotherapy approaches.